نتایج جستجو برای: monotherapy hematopoietic

تعداد نتایج: 73323  

2016
Juan Feng Xuan Zhang Li-Jie Yang Xie-Qun Chen Hong-Juan Dong Guang-Xun Gao

Plasmablastic lymphoma (PBL) is a relatively rare and high grade B cell lymphoma. It often occurs in oral cavity of patients with human immunodeficiency virus (HIV) infection, but it can also be seen in HIV-negative patients. PBL presents a therapeutic challenge to clinicians due to its aggressive clinical feature and high relapse rates. No standard treatment guidelines are formulated. Conventi...

2014
Jun Aoki Kiminori Kimura Kazuhiko Kakihana Kazuteru Ohashi Hisashi Sakamaki

INTRODUCTION Hepatitis B virus (HBV) flare is a serious problem following hematopoietic stem cell transplantation (HSCT), and the mortality rate is high if severe hepatitis occurs. CASE DESCRIPTION Although Entecavir (ETV) is a standard antiviral drug for HBV infection, the efficacy and safety of ETV therapy in HSCT are still unclear. DISCUSSION AND EVALUATION To examine the efficacy and to...

2005
Dian L. Olson Linda C. Burkly Diane R. Leone Brian M. Dolinski Roy R. Lobb

In a syngeneic murine model of multiple myeloma with many of the characteristics of the human disease, a monoclonal antibody (mAb) to the integrin very late antigen-4 (VLA-4), given after the myeloma has already homed to and begun to establish itself within the bone marrow compartment, produces statistically significant effects on multiple disease variables. These include reductions in circulat...

2016
Huijie Jia Tiesuo Zhao Yinghua Ji Xiaolong Jia Wenjing Ren Chen Li Minming Li Yali Xiao Hui Wang Kailin Xu

Acute graft-versus-host disease (aGvHD) is the major barrier to the broader use of allogenetic hematopoietic stem cells. However, currently these are no highly specific and efficient drugs. Monotherapy is not sufficient and more efficient and safe therapeutic regimen are urgent need. Studies demonstrated TLR9 and Stat3 signal pathways are critical for antigen-presenting cell maturation and T-ce...

Journal: :Molecular cancer therapeutics 2005
Dian L Olson Linda C Burkly Diane R Leone Brian M Dolinski Roy R Lobb

In a syngeneic murine model of multiple myeloma with many of the characteristics of the human disease, a monoclonal antibody (mAb) to the integrin very late antigen-4 (VLA-4), given after the myeloma has already homed to and begun to establish itself within the bone marrow compartment, produces statistically significant effects on multiple disease variables. These include reductions in circulat...

2015

Background: Dose-intensive chemotherapy with hematopoietic stem cell transplantation has been evaluated as a salvage treatment for recurrent ovarian cancer, but its benefit has not yet been demonstrated. In a previous phase I trial, we reported the feasibility of administering topotecan as a salvage regimen. Methods: Twenty-one patients were treated with escalating doses of topotecan associated...

2012
Michaela Döring Angelika Zierl Markus Mezger Peter Lang Rupert Handgretinger Ingo Müller

Systemic fungal infections are a major cause of infection-related mortality in patients with hematologic malignancies. This report addresses the case of an adolescent patient with acute lymphoblastic leukemia who underwent three allogeneic hematopoietic stem cell transplantations and developed pulmonary aspergillosis. Combination therapy with liposomal amphotericin B (L-AmB, 3 mg/kg bw/day) and...

2015

Background: Dose-intensive chemotherapy with hematopoietic stem cell transplantation has been evaluated as a salvage treatment for recurrent ovarian cancer, but its benefit has not yet been demonstrated. In a previous phase I trial, we reported the feasibility of administering topotecan as a salvage regimen. Methods: Twenty-one patients were treated with escalating doses of topotecan associated...

Journal: :international journal of hematology-oncology and stem cell research 0
ardeshir ghavamzadeh hematology- oncology and stem cell transplantation research center, shariati hospital, tehran university of medical sciences, tehran, iran amir ali hamidieh hematology- oncology and stem cell transplantation research center, shariati hospital, tehran university of medical sciences, tehran, iran mohammad jahani hematology- oncology and stem cell transplantation research center, shariati hospital, tehran university of medical sciences, tehran, iran

introduction: allogeneic hematopoietic cell transplantation (hsct) is the only therapeutic modality capable of correcting the hematologic manifestations of fanconi anemia (fa). the development  of well  tolerated,  immunosuppressive  conditioning  regimens  for fa patients  undergoing hsct has proven to be a rather challenging task for hematologists. methods: we analyzed the outcome of 30 fa pa...

Journal: :iranian red crescent medical journal 0
ardeshir ghavamzadeh hematology, oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, ir iran kamran alimoghaddam hematology, oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, ir iran; hematology, oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, ir iran. email: fatemeh ghaffari hematology, oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, ir iran roshanak derakhshandeh hematology, oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, ir iran arash jalali hematology, oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, ir iran mohammad jahani hematology, oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, ir iran

conclusions in iran, hsct has been successfully adapted in routine clinical care. recently, new methods such as double cord blood and haploidentical transplantation have been used to treat many life-threatening diseases. results about 78.2% of the patients (2530 of 3237) remained alive between one to 211 months after stem cell transplantation. nearly, 21.8% (707) of our patients died after stem...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید